Philips ships two-millionth AED, helping to save lives across the globe
July 03 2019 - 9:00AM
Philips ships two-millionth AED, helping to save lives across the
globe
July 3, 2019
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced shipment of its two-millionth AED (Automated External
Defibrillator), which was delivered to a customer in Italy. This
achievement marks a major milestone in almost 20 years of Philips
innovation in cardiac resuscitation aimed at providing personalized
therapy to victims of sudden cardiac arrest. Cardiac arrests can
happen anywhere, at any time, and bystander intervention and
treatment with an AED has been shown to triple the survival rate to
31.4 percent [1].
“We are very proud of the knowledge that
Philips AEDs have helped to save lives every day for almost two
decades,” said Arman Voskerchyan, Business Leader Therapeutic Care
at Philips. “As we have reached the incredible milestone of
shipping our two-millionth AED worldwide, we will continue to
provide our customers with reliable, easy-to-use lifesaving
solutions.”
Earlier this year, Philips and the American Heart Association
announced a collaboration to increase sudden cardiac arrest
survival rates in densely populated cities around the world.
The Connected Pulse program leverages a unique end-to-end
solution combining education programs to increase awareness of CPR
(Cardiopulmonary Resuscitation), the use of publicly available
AEDs, and new technologies to strengthen the ‘chain of survival’
from the moment an incident occurs to the patient reaching the
hospital.
A pioneer in AED
innovationPhilips’ HeartStart OnSite AED made the
implementation of early AED programs in communities, schools and
businesses much easier, while the Philips HeartStart Home AED
remains the only AED available in the US for home use. Philips was
also the first to introduce an AED for pediatric use, and was a
pioneer in providing AEDs for use in airplanes. Today, Philips AEDs
are available across the globe, on board major airlines, in Fortune
100 companies, and in the locker rooms of professional sports teams
worldwide.
Philips recently announced that the US Food and Drug
Administration (FDA) has approved the company’s premarket approval
(PMA) application for its HeartStart OnSite AED [2] and HeartStart
Home AED [3], and the relevant accessories, such as batteries and
electrodes [4].
More information on Philips’ portfolio of AEDs and the
two-millionth AED milestone is available here.
[1] Response to Cardiac Arrest and Selected
Life-Threatening Medical Emergencies, Mary Fran Hazinski; et al,
American Heart Association, September 16, 2016[2] Model
M5066A[3] Model M5068A[4] Battery Model
M5070A. SMART Pads Cartridges Models M5071A and M5072A
For further information, please contact:
Joost MalthaPhilips Group Press OfficeTel. : +31 6 10 55
8116E-mail : joost.maltha@philips.comTwitter: @joostmaltha
Kathy O’ReillyPhilips Group Press OfficeTel. : +1
978-221-8919E-mail : kathy.oreilly@philips.comTwitter:
@kathyoreilly
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2018
sales of EUR 18.1 billion and employs approximately 77,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Apr 2023 to Apr 2024